Contraindications of metoprolol
Pro Research Analysisby 
Searched over 200M research papers
Contraindications of Metoprolol
Peripheral Vascular Disease (PVD) and Metoprolol
Peripheral Vascular Disease Contraindications
Metoprolol, a beta-1 selective beta-blocker, was traditionally considered relatively contraindicated in patients with peripheral vascular disease (PVD). However, recent studies have shown that metoprolol can be safely administered to hypertensive patients with PVD without significant adverse effects on peripheral circulation. In a study involving hypertensive patients with PVD, metoprolol did not significantly decrease blood flow in the posterior tibial artery and even improved pain-free walking distance .
Gender Differences in Dosage
Gender-Specific Dosage Considerations
Although current guidelines do not provide sex-specific dosage recommendations for metoprolol, observational studies have found that women are often started on lower daily doses compared to men. This discrepancy could potentially lead to confounding by contraindication in pharmacoepidemiological studies, suggesting a need for more tailored dosage guidelines .
Stable Angina Pectoris and Metoprolol
Exclusion Criteria in Angina Studies
In studies involving patients with stable angina pectoris, exclusion criteria for metoprolol included recent myocardial infarction and other contraindications to beta-blockers. These studies have shown that metoprolol is well-tolerated and effective in managing angina symptoms, with no significant difference in cardiovascular events compared to other treatments like verapamil .
Acute Myocardial Infarction (AMI) and Metoprolol
Contraindications in AMI Treatment
In the context of acute myocardial infarction (AMI), metoprolol is contraindicated in patients with a heart rate of 65 beats per minute or lower, systolic blood pressure of 105 mm Hg or lower, and those already on beta-blockers or calcium-channel blockers. These criteria are crucial to avoid adverse effects and ensure patient safety during early intervention .
Chronic Obstructive Pulmonary Disease (COPD) and Metoprolol
COPD Exacerbation Risks
Metoprolol is generally contraindicated in patients with chronic obstructive pulmonary disease (COPD) due to the risk of exacerbations. A randomized trial found that metoprolol did not significantly delay the time to the first COPD exacerbation and was associated with a higher risk of hospitalization for exacerbations, highlighting the need for caution in this patient population .
Post-Coronary Artery Bypass Grafting (CABG) and Metoprolol
Post-Surgical Contraindications
In patients undergoing coronary artery bypass grafting (CABG), traditional contraindications to beta-blockers, including metoprolol, must be considered. These include age over 75 years, concomitant valve surgery, and other standard contraindications. Studies have shown that metoprolol does not significantly reduce death or cardiac events post-CABG, emphasizing the importance of individualized patient assessment .
General Contraindications and Side Effects
Common Contraindications and Side Effects
Metoprolol is contraindicated in patients with severe bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure. Common side effects include fatigue, dizziness, and headache, which are generally mild but can be clinically significant, especially in long-term therapy 56.
Conclusion
Metoprolol, while effective for various cardiovascular conditions, has several contraindications that must be carefully considered. These include specific conditions like PVD, COPD, and certain post-surgical states, as well as general contraindications such as severe bradycardia and heart block. Tailoring the dosage and monitoring for side effects are crucial for optimizing patient outcomes.
Sources and full results
Most relevant research papers on this topic